"Designing Growth Strategies is in our DNA"
The global heparin market size was valued at USD 9.53 billion in 2022 and is projected to grow from USD 9.89 billion in 2023 to USD 13.22 billion by 2030, exhibiting a CAGR of 4.2% during the forecast period.
Heparin is considered as one of the most critical life-saving drugs available in the world currently. It can be used for the management and treatment of various chronic diseases. This product belongs to the anticoagulant class of drugs and is used as a therapy for several cardiovascular diseases, including deep vein thrombosis and pulmonary embolism. However, the market suffered from several undesirable causes, such as product contamination, and issues concerned with supply chain disruption in past years. Despite that, the crucial nature of the drug has led to its persistent existence by several major companies, such as Baxter and Pfizer, aiding the global market growth during the forecast period.
Moreover, there has been considerable evidence that supports the hypothesis. Apart from this product’s anticoagulant properties, it also possesses significant anti-inflammatory properties, due to which the market is expected to grow during the forecast period. Such benefits attributed to this product and various R&D initiatives are expected to boost the global market growth further.
Critical Nature of these Products and Increased Incorporation into COVID-19 Treatment Protocols Enabled the Market’s Steady Growth
The COVID-19 pandemic had a positive impact on the global market as the drug is considered a life-saving medication for certain chronic disorders. This resulted in increased demand for heparin products. At the same point, the accumulation of certain types of the product along with the usage of this product as a COVID-19 therapeutic has stimulated the demand for certain treatment procedures. However, in some instances, the pandemic posed certain barriers to global market growth in the initial days due to a sharp reduction in hospital visits worldwide and supply issues of essential materials that are required to be sourced from China. After the outbreak, the global market recovered well from the initial negative impact of the pandemic.
Also, the pandemic exerted a negative impact in the initial days of the pandemic on the sales of these products across the globe due to the reduction of hospital visits and a strong decline in the number of cardiovascular disease diagnoses. However, in 2021, several R&D initiatives toward the treatment and management of COVID-19 led certain researchers to study the efficacy of the U.S. FDA-approved heparin as a neutralizer of the virus.
Request a Free sample to learn more about this report.
Increasing R&D Initiatives for Synthetic Heparin to Escalate Trade Openings
In terms of technological advancements, there have been continuous initiatives undertaken by government authorities as well as operating players to expand these products’ applications as well as introduce alternatives to animal-derived products. However, the criticality and importance of this therapy during the anticoagulation process remain unaffected. Another reason such as the availability of porcine raw material for the drug's development and manufacturing has caused global concerns, especially for the U.S. market. Furthermore, current research initiatives focus on the control of enzymes that regulate these drugs and offer great potential in terms of the development and preparation of synthetic unfractionated heparin, LMWH, and Ultra Low Molecular Weight Heparin (ULMWH).
The development of the synthetic version can give rise to products with reduced side effects of Heparin-induced Thrombocytopenia (HIT) and with more defined physical, chemical, biological, and pharmacological properties. For instance, a new synthetic version of sulfated polysaccharide heparin is expected to have a better safety profile and more-reversible activity than the currently approved versions of the anticoagulant.
Furthermore, some of the emerging players such as Optimvia, Midas Pharma GmbH, and others are collaborating to introduce synthetic variants of these products at a cheaper cost to replace animal-derived products.
Such strategic initiatives have provided impetus to market players to introduce an alternative to crude heparin API through the upscaling of R&D activities coupled with partnerships with native players. Cumulatively, all these factors will significantly boost the global market growth during the forecast period.
Increased Incidence of Cardiovascular and Other Chronic Disorders to Boost Market Growth
A critical driving factor that will influence the global market is the rising prevalence of cardiovascular diseases, which will fuel the demand for these products. Almost every form of cardiovascular disease such as heart attacks, strokes, venous thromboembolism, and other related conditions, such as atrial fibrillation, are expected to remain prevalent in the forthcoming years.
Such trends and statistics represent substantial potential and existing patient populations worldwide, which are influencing the strong demand for these products. Furthermore, increasing awareness amongst patients regarding the efficiency of these drugs for the treatment of various heart diseases will drive the market growth.
Robust Adoption of the Product in Various Applications to Stimulate Market Growth
Efficacy of these drugs as an anticoagulant is another key factor that is anticipated to drive global market growth. Furthermore, undeniable factors such as advancements in technology and launch of innovative products in the forecast period are prominently expected to drive the growth of the global market.
The consistent surge in the usage of these drugs has further initiated advancements in the development of LMWH. Furthermore, technological advancements have given rise to newer forms such as Ultra-low Molecular Weight Heparin (ULMWH). Hence, these factors are expected to impact the market during the forecast period positively.
Shortage of Raw Material Coupled with Higher Prices of Certain Types to Restrain Market Growth
One of the critical restraining factors that affect the growth of the global market is an insufficient supply of raw materials from China for the manufacturing of porcine-based versions of this product. Multiple recent outbreaks of African Swine Fever (ASF) in China, which is a fatal disease for the swine, have led to the widespread culling of pigs to control outbreaks.
Hence, these factors might lead to the continued shortage of raw materials for the manufacturing of these products. The second restraining factor is the higher costs associated with LMWH, which might limit its greater adoption in developing markets and is anticipated to restrict market growth in the forthcoming years.
To know how our report can help streamline your business, Speak to Analyst
Superior Advantages Offered by LMWH Products to Propel Segment’s Growth
On the basis of product, the market is segmented into Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH).
The LMWH segment held a dominant global heparin market share in 2022. The dominance of this segment is due to the high adoption rate of this product in developed markets and greater safety profiles of these products in comparison to others. Some important LMWH products include Fragmin (Dalteparin sodium), Lovenox (Enoxaparin sodium), and Innohep (Tinzaparin sodium). Several market players are also focusing on the development and launches of new LMWH products in the global market. For instance, in November 2019, Valeo Pharma Inc. announced that it filed a New Drug Submission for LMWH biosimilar, which has been accepted for review by Health Canada.
However, the UFH segment is anticipated to register a lower market share in the forecast period. This is primarily due to the increasing transition toward the usage of LMWH and the concerns associated with safety profiles of this product.
High Adoption Rate Led to Porcine Segment’s Dominance in 2022
Based on source, the market can be segmented into bovine and porcine.
The porcine segment is anticipated to dominate the market during the forecast period as key markets such as North America and Europe are some of the regions where porcine-based products are the only permitted version derived from an animal-based source. The growth of the segment is attributable to the increasing rate of diagnosis of cardiovascular diseases in emerging and developed countries. Lack of availability of other animal-based alternatives as an anticoagulant is set to increase the adoption rate. Hence, this segment maintains an undisturbed dominance in the global market.
Bovine, which is present in certain Islamic and Latin American countries, accounted for a lower share of the global market and also registered a comparatively lower CAGR. However, the bovine segment is expected to witness positive growth in the forecast period as developed countries such as the U.S. are planning to reintroduce this product to meet the growing demand. For instance, in February 2020, a study published in Frontiers in Medicine reported that the bovine -based version of the product can be used as an alternative to conventional porcine based version of the product in the U.S. as it produces an acceptable level of impurity mentioned by the U.S. Pharmacopeia.
High Incidence Rate of Heart Attacks will Propel the Market Growth in 2023-2030
In terms of application, the market is segmented into deep vein thrombosis & pulmonary embolism, atrial fibrillation, heart attacks, stroke, and others.
The heart attacks segment is expected to dominate the market due to significant proportion of the populace suffering from this disease for which one of the most important interventions is the administration of injectable anticoagulants.
The atrial fibrillation segment is anticipated to be the second-largest segment in the forecast period since a sizable proportion of the global populace suffers from the disease.
The deep vein thrombosis & pulmonary embolisms and strokes segments also account for significant market shares during the forecast period as the product is an important treatment option for these medical conditions. As per an article published by the Journal of American College of Cardiology (JACC) in February 2021, the overall incidence of deep venous thrombosis & pulmonary embolism is estimated to be 1 to 2 per 1,000 person-years across the world. In the same article, it was further stated that atrial fibrillation increases the risk of stroke by 4-5 times and accounts for an estimated 15%-20% of ischemic strokes.
The others segment consists of application areas such as administration during hemodialysis and is expected to register a comparatively lower CAGR over the forecast period.
Advantages Offered by Subcutaneous Injection Segment over Intravenous Administration Led to the Segment’s Dominance in 2022
By route of administration, the market is segmented into intravenous infusion and subcutaneous injection.
The subcutaneous injection segment is anticipated to dominate the market. This is attributed to the fact that LMWH is usually administered subcutaneously. The growth of the segment is attributable to technological advancements and sophistication of subcutaneous injection as compared to other administration types. Additionally, some of the advantages attributed to this route of administration include the elimination of the need for constant laboratory monitoring to check the patient’s anticoagulation response.
The intravenous infusion segment is anticipated to register a comparatively lower growth rate in the forecast period. It includes several prominent product offerings of UFH that can be administered intravenously. For example, as per an article published in 2020 by the National Institutes of Health (NIH), in severe renal impairment, a rapid offset of anticoagulant is required, which is administered through intravenous infusion.
Dependency on Healthcare Professionals for Administration is Expected to Drive Hospitals & ASCs Segment’s Growth in 2023-2030
Based on end-user, the market is segmented into hospitals & ASCs, clinics, and others.
The hospitals & ASCs segment is expected to account for the highest share of the global market in the forecast period. This is fundamentally due to greater dependency on healthcare professionals for prescribing these products, along with proper administration, especially through intravenous infusion.
The clinics segment is expected to account for the second-largest market share during the forecast period as many of these products are administered at dialysis clinics. The others segment is expected to witness high CAGR primarily due to an increase in the use of LMWH through subcutaneous administration at homecare settings. The product is also available through retail pharmacies. This is attributed to the fact that home care settings offer the patient greater ease and convenience.
North America Heparin Market Size, 2022 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
On the basis of region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The market size in North America stood at USD 4.87 billion in 2022 and the region is expected to account for the dominant share of the global market during the forecast period. North America dominates the global market due to the region’s strong prevalence of cardiovascular disorders such as pulmonary embolism, higher adoption of advanced products, strong healthcare expenditure, and the presence of significant market players engaged in these product sales. For instance, according to the estimates by the Centers for Disease Control and Prevention (CDC) in October 2022, every year, an estimated 805,000 individuals in the U.S. suffer from a heart attack, out of which 605,000 were newly reported cases.
The market in Europe is anticipated to be the second-largest market in the globe owing to the strong adoption of technologically advanced products in the region along with an increase in the number of individuals suffering from a range of cardiovascular diseases. For instance, as per an article published by the U.K. government in February 2022, in the U.K. about 1 in 1,000 people are affected by venous thrombosis each year.
The Asia Pacific market is expected to register the highest CAGR in the forecast period due to increased need for technologically sophisticated products, a strong potential patient population, and a significant surge in healthcare expenditure. As per an article published by the Journal of the American College of Surgeons in 2020, administration of LMWH in Japanese patients after a laparoscopic operation for gastrointestinal malignancy is safe to prevent venous thromboembolism. Growing applications of LMWH in diverse application areas in the region including postoperative treatment, will likely to drive the market’s growth during the forecast period.
The other regions such as Latin America and the Middle East & Africa are anticipated to account for a comparatively lesser market share in the forecast period. However, these regions are expected to register strong growth prospects in the forecast period due to increased healthcare expenditure. Further, greater awareness of timely treatment of chronic illnesses such as cardiovascular diseases is expected to boost product demand. For instance, in February 2020, according to an article published by Global Heart, an official journal for the World Heart Federation, 13% of all deaths in sub-Saharan Africa occur due to cardiovascular diseases. Furthermore, 23% of the world’s rheumatic heart disease cases are prevalent in sub-Saharan African regions. Increased awareness in the general population regarding these diseases is anticipated to contribute to greater product adoption rates.
Robust Product Portfolio of Pfizer Inc., Baxter, and Sanofi-Aventis Led to their Dominant Market Position in 2022
In the competitive scenario, the global market is characterized by the presence and dominance of a few key companies such as Pfizer Inc., Baxter, and Sanofi-Aventis. In the current competitive scene, Pfizer, Inc. and Baxter dominated the global market in 2022, accounting for a strong market revenue share. The dominance of these market players is attributable to their strong and robust product portfolio, which comprises several products including UFH and LMWH offerings. For example, Pfizer, Inc. is a dominant company due to its prominent product offering of Fragmin (Dalteparin sodium), a LMWH product.
Other important players include Baxter and Sanofi whose presence is mainly due to their product offerings, Heparin Sodium & 0.9% Sodium Chloride Injection and Lovenox (Enoxaparin Sodium), respectively. Some other emerging market players include Opocrin S.p.A. and Aspen Holdings, and these companies’ market expansion strategies are anticipated to aid them in increasing their market revenue share in the forecast period.
To gain extensive insights into the market, Request for Customization
The global heparin market research report provides a detailed analysis of the market and focuses on key aspects such as key industry developments - mergers, acquisitions, and partnerships, new product launches, prevalence of key cardiovascular diseases by key countries, an overview of technological advancements, the impact of COVID-19 pandemic on the market, regulatory scenario by key countries, reimbursement scenario by key countries, trends of consumption in Muslim-oriented markets, insights on the usage of UFH & LMWH, China market overview (production/supply impacted by swine fever), purchasing process, and pricing. Besides this, the report offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the global market in recent years.
CAGR of 4.2% from 2023-2030
Value (USD billion)
By Product, Source, Application, Route of Administration, End-user, and Region
By Route of Administration
Fortune Business Insights says that the global market size was USD 9.53 billion in 2022 and is projected to reach USD 13.22 billion by 2030s.
In 2022, North America stood at USD 4.87 billion.
Growing at a CAGR of 4.2%, the market will exhibit steady growth in the forecast period (2023-2030).
The LMWH segment is expected to be the leading segment in this market during the forecast period.
The increasing prevalence of cardiovascular diseases, strong demand from a large patient population base, and technological advancements are major factors driving the growth of the market.
Pfizer, Inc. and Baxter are some of the major market players in the global market.
North America dominated the market in 2022.
New product launches by key companies and increasing prevalence of diseases necessitating the need for these products are expected to drive the adoption of the product in the global market.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry